Trial Profile

Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 28 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fluorine 18 flotufolastat (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Diagnostic use

Most Recent Events

23 May 2024 Status changed from not yet recruiting to recruiting.
27 Jan 2024 Trial design presented at the 2024 Gastrointestinal Cancers Symposium.
16 Jan 2024 According to a Blue Earth Diagnostics media release, role of 18F-flotufolastat PET/CT imaging from this trial will be presented at the upcoming ASCO GU 2024 Genitourinary Cancers Symposium (ASCO GU) held in San Francisco, Calif., from January 25 to 27, 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com